ArticleAnnals of hematology2025
Epidemiologic trends for pediatric Hodgkin and non-Hodgkin lymphomas: a U.S. population-based study.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Descriptive Case Series of Childhood Lymphomas Treated at the Children's Hospital of Mexico.Pediatric reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are distinct from adult forms and occur less frequently. We identified 7,871 children and 226,211 adults with lymphoma from the Surveillance, Epidemiology, and End Results database from 1975 to 2018. The age-adjusted incidence rate for pediatric lymphoma was 24.5 per million persons (95% CI: 24.0-25.1), comprising 13.0 per million (95% CI: 12.6-13.4) for HL and 11.5 per million (95% CI: 11.1-11.9) for NHL. In comparison to adult lymphoma, pediatric lymphoma showed no significant changes in incidence from 1975 to 2002 (annual percentage change, APC = -0.12 ± 0.19, P = 0.53), but displayed an observable increase after 2003 (APC = + 1.31 ± 0.45, P = 0.006). Among pediatric cases, the 5-year limited-duration prevalence rate increased from 0.00691% in 1996 to > 0.009% in recent years, and the 20-year rate rose from 0.0109% in 1996 to 0.0148% in 2018. In alignment with the observed decrease in incidence over the recent decade, the prevalence of adult lymphoma exhibited a more gradual growth post-2007. Among adult patients, the age-adjusted mortality rate demonstrated an initial increase in the periods 1975-1977 (APC = + 41.06 ± 6.23, P < 0.001), 1977-1980 (APC = + 9.83 ± 4.27, P = 0.036), 1980-1989 (APC = + 5.24 ± 0.36, P < 0.001), and 1989-1994 (APC = + 2.27 ± 0.86, P = 0.014), followed by a subsequent decrease after 1994 (APC= -0.49 ± 0.05, P < 0.001). In contrast, the mortality rates of pediatric lymphoma exhibited a consistent decrease over the past four decades (1975-2018: APC= -3.12 ± 0.29, P < 0.001), resulting in an overall age-adjusted mortality rate of 2.92 (95% CI: 2.73-3.11).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.